Lilly has a White House pricing deal, and CMS plans to exempt such firms from a rule expected to reach few drugs. PhRMA’s suit seeks to block it, but the savings estimate fell to $440 million over 7 years from $11.9 billion, leaving Lilly’s outlook little changed.
The rule could lower Medicare payments for some medicines. Lilly is among companies with White House pricing deals, which CMS plans to exempt. The rule is expected to reach few drugs, and the reported savings estimate fell sharply. PhRMA’s suit seeks to block the rule, but no ruling is reported. Together, these facts point to little change for Lilly so far.
Pfizer has a White House pricing deal, and CMS plans to exempt such firms from a rule expected to reach few drugs. PhRMA’s suit seeks to block it, but the savings estimate fell to $440 million over 7 years from $11.9 billion, leaving Pfizer’s outlook little changed.
Novo Nordisk has a White House pricing deal, and CMS plans to exempt such firms from a rule expected to reach few drugs. PhRMA’s suit seeks to block it, but the savings estimate fell to $440 million over 7 years from $11.9 billion, leaving Novo Nordisk’s outlook little changed.
Follow Eli Lilly and Co. (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LLY